Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on September 8, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Rob Myers, M.D. appointed Chief Medical Officer, expected to start September 21, 2026.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Rob Myers, M.D. appointed Chief Medical Officer, expected to start September 21, 2026
- Joanne Quan, M.D. ceased serving as Chief Medical Officer September 2, with employment termination expected October 19, 2026
- Quan expected to receive Severance Plan benefits following an anticipated involuntary termination
- Vested options’ post-termination exercise window extended to 12 months after separation
- 2026 target bonus payable at 100% achievement on the Separation Date, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.